CG
LXRX icon

Cutler Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cutler Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-62,210
Closed -$646K – 5469
2017
Q3 		$764K Buy
62,210
+61,572
+9,651% +$909K 0.03% 446
2017
Q2 		$10K Sell
638
-3,398
-84% -$52.6K ﹤0.01% 4159
2017
Q1 		$57K Sell
4,036
-10,218
-72% -$152K ﹤0.01% 2276
2016
Q4 		$197K Sell
14,254
-19,883
-58% -$319K 0.01% 1308
2016
Q3 		$616K Buy
34,137
+9,300
+37% +$150K 0.03% 518
2016
Q2 		$356K Sell
24,837
-7,115
-22% -$96.5K 0.02% 770
2016
Q1 		$381K Buy
31,952
+15,528
+95% +$163K 0.03% 644
2015
Q4 		$218K Buy
+16,424
New +$202K 0.01% 1123

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Cutler Group's LXRX Position: Q4 2017 in Review

Cutler Group sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 62,210 shares — an estimated $646K sold.

Cutler Group first reported a position in LXRX in Q4 2015 and held it in 8 quarters. The position peaked at $764K in Q3 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Cutler Group reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 62,210 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $646K.
  • Cutler Group first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Lexicon Pharmaceuticals position peaked at $764K in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.